MetaVia Showcases Innovative Therapies for Obesity at Life Sciences Investor Forum

MetaVia to Showcase Leading-Edge Treatments for Obesity

MetaVia Inc., a biotechnology firm on the NASDAQ trading under the ticker MTVA, is making headlines with its commitment to revolutionizing the treatment of cardiometabolic diseases. On March 12, 2026, the company is set to participate in the Life Sciences Virtual Investor Forum. Hyung Heon Kim, the President and CEO, will lead a focused discussion on their promising pipeline of obesity and metabolic therapies.

This virtual event, co-hosted by Zacks Small Cap Research, promises a dynamic platform for interaction where investors can engage with the company during a live Q&A session. The format allows for real-time inquiries, making it an enriching experience for participants looking to understand more about the innovations spearheaded by MetaVia. For those unable to attend the live stream, the forum will provide an archived version for later viewing. It’s advisable for potential investors to pre-register through the provided link to ensure smooth access and receive timely updates about the event.

MetaVia is particularly excited to discuss two of its lead candidates: DA-1726 and vanoglipel.
DA-1726 is a novel oxyntomodulin analogue that functions as a dual agonist activating both glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR). This innovative approach is expected to decrease food intake while enhancing energy expenditure, promoting more significant weight loss compared to traditional therapies focused solely on GLP1R. Early Phase 1 trials indicate that DA-1726 has superior potential for weight loss, glucose management, and waist circumference reduction among its competitors in the market.

On the other hand, vanoglipel acts as an agonist for the G-protein-coupled receptor 119 (GPR119), stimulating the release of essential gut hormones such as GLP-1, GIP, and PYY. Pre-clinical studies suggest significant benefits, including reduced liver inflammation, lipid metabolism improvement, weight loss, and better glucose regulation—key factors for addressing conditions like Metabolic Dysfunction-Associated Steatohepatitis (MASH). The clinical data from the Phase 2a study showcases vanoglipel’s direct action on the liver alongside its glucose-lowering capabilities.

MetaVia's continued dedication toward tackling obesity and metabolic disorders is fueling anticipation within the investment community about the potential of their innovative treatments. With the nature of rising public health concerns regarding obesity, their contributions could prove to be crucial at this juncture.

Moreover, the company will also facilitate one-on-one meetings for investors interested in deeper discussions about its products and future directions. Interested parties can register for these exclusive opportunities through a separate link provided by the company.

For more detailed information about their clinical trials and research, individuals can visit the official MetaVia website: www.metaviatx.com.

As MetaVia prepares for the Life Sciences Virtual Investor Forum, the industry watches closely, aware that the breakthroughs in their development pipeline could mark pivotal moments in combating obesity and enhancing metabolic health. This forum is not just an opportunity to showcase their scientific advancements but also a significant chance to engage with investors keen on supporting next-gen therapies poised to reshape patient outcomes in the field of cardiometabolic diseases.